In contrast, the MDS/secondary AML group more frequently had mutations in ASXL1, ETV6, and SRSF2 genes (p=0.007, 0.023, and 0.007, respectively: Table S1). This evidence concerns the gene SRSF2 and acute myeloid leukemia.